

Supplemental table 1. Demographic, clinic and biomolecular data concerning all the investigated patients.

Sample name	Sex	Age at diagnosis (years)	Stage*	Monoclonal component	TC [§]	HD [¶]	del(13) [‡]	del(17p) [‡]	+1q [‡]
MM-015	M	70	II A	Gk	1	-	+	-	-
MM-026	F	73	IIIB	k	1	nd	-	-	-
MM-031	M	57	IIIA	Ak	1	+	-	-	+
MM-052	F	39	IA	Gλ + Aλ	1	-	+	-	+
MM-055	F	69	IIIA	Gk	1	-	-	-	-
MM-111	M	73	IA	Gλ	1	-	-	-	-
MM-115	F	53	IIIA	k	1	-	+	-	+
MM-126	M	62	IIA	Ak	1	nd	-	nd	nd
MM-140	M	61	IIIB	nd	1	-	-	-	-
MM-179	M	50	IIIA	Gλ	1	+	-	+	-
MM-212	F	55	IIIA	nd	1	-	-	-	-
MM-246	M	nd	nd	nd	1	-	-	-	-
MM-030	M	69	IIIA	Gλ	2	+	-	-	-
MM-034	M	72	IA	Gk	2	+	-	-	-
MM-035	M	74	IA	Gk	2	nd	-	-	-
MM-038	F	67	IIA	k	2	+	+	-	-
MM-039	M	49	IIA	Gλ	2	+	-	-	-
MM-043	F	73	IA	Gk + Gλ	2	-	-	-	+
MM-049	M	63	IIIB	k	2	+	-	-	-
MM-056	M	72	IA	Gk	2	nd	-	-	nd
MM-079	F	74	IIA	Gk + Gλ	2	+	-	-	-
MM-131	M	69	IA	Gk	2	+	-	-	-
MM-143	M	56	IIA	Gk	2	+	-	-	-
MM-151	F	72	IA	Gλ	2	+	-	-	-
MM-243	F	68	nd	nd	2	+	-	-	+
MM-016	M	66	IIIB	Gk	3	+	-	-	+
MM-027	M	61	IA	Gk	3	+	+	-	+
MM-036	M	66	IIA	Gk	3	-	+	-	+
MM-040	F	77	IIIB	Gλ	3	+	+	-	+
MM-050	M	71	IA	Aλ	3	nd	-	-	nd
MM-081	M	79	IA	Ak	3	nd	nd	nd	nd
MM-094	M	nd	IA	Aλ	3	-	+	-	+
MM-177	M	73	IIIA	Gk	3	-	+	-	+
MM-229	M	75	IIA	Gk	3	-	-	-	-
MM-239	F	72	nd	A	3	+	+	-	-
MM-253	F	46	nd	λ	3	+	+	-	+
MM-295	F	74	nd	λ	3	nd	+	-	nd
MM-021	M	52	nd	nd	4	-	+	+	+
MM-042	M	54	IIIA	Aλ	4	+	+	-	+
MM-066	F	78	IIIA	Ak	4	-	-	-	-
MM-074	M	69	IIIA	Ak	4	+	+	-	+
MM-083	M	72	IA	Gλ	4	-	+	-	+
MM-087	F	85	IIIA	Gλ	4	-	+	-	+
MM-104	F	63	IIIA	Aλ	4	-	+	-	+
MM-123	M	56	IIIA	Gk	4	-	+	-	+
MM-195	M	63	nd	Gk	4	-	+	-	-
MM-206	F	73	IA	Gk	4	-	+	-	- [‡]
MM-208	M	75	nd	Aλ	4	+	-	-	-
MM-233	M	75	IIIA	Gλ	4	-	+	-	+
MM-004	F	58	IA	Gk	5	nd	-	nd	nd
MM-025	F	64	IA	Gλ	5	-	+	-	+
MM-069	M	66	IIA	Gk	5	-	+	-	+
MM-154	F	71	IIA	G	5	-	+	-	+
MM-224	F	53	IIIA	Gk	5	-	-	-	+
MM-335	F	68	nd	nd	5	-	+	-	+
PCL-005	M	76	PCL	Ak		+	-	-	+
PCL-006	M	55	PCL	Gk		nd	-	+	nd
PCL-007	M	66	PCL	k		nd	nd	+	+
PCL-009	F	78	PCL	nd		-	+	-	+
PCL-011	M	76	PCL	Gk		-	+	+	+
PCL-013	M	76	PCL	Aλ		-	-	-	+
PCL-031	F	nd	PCL	nd		nd	-	+	nd
PCL-033	F	75	PCL	λ		nd	+	-	nd

*The Durie clinical staging system was adopted. [§]The TC (translocation/cyclin D expression) group according to Hideshima classification is indicated. [¶]HD = presence of the hyperdiploid status on the basis of FISH evaluation criteria. [‡]del(13), del(17), 1q gain/amplification were determined by FISH and/or microarray genome-wide analysis. [‡]FISH revealed multiple copies of the *BCL9* locus (1q21.1), and two copies of the *ARF9* locus (1q42.13)[§], so the patient was not considered in the supervised analysis regarding 1q gain.